Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
126 hedge funds and large institutions have $387M invested in Intercept Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 42 reducing their positions, and 34 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 42
1% more capital invested
Capital invested by funds: $385M → $387M (+$2.74M)
13% less funds holding
Funds holding: 144 → 126 (-18)
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
70% less call options, than puts
Call options by funds: $9.77M | Put options by funds: $32.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$29M |
| 2 |
BlackRock
New York
|
+$18.6M |
| 3 |
CP
Caligan Partners
New York
|
+$18M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$9.19M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.73M |
| 3 |
Goldman Sachs
New York
|
-$6.49M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.89M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.33M |
ICPT Hedge Fund Activity: Q2 2023 in Review
126 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2023, worth a combined $387M — up 0.71% from $385M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ICPT and 16 opened new positions — a net loss of 18 holders — while 42 trimmed existing stakes and 46 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $29M. The largest seller was Macquarie Group, cutting an estimated $9.19M.
- 126 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2023, down from 144 in Q1 2023.
- Funds reported $387M of Intercept Pharmaceuticals, Inc. stock for Q2 2023, up 0.71% quarter-over-quarter.
- 16 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2023 and 34 closed out, a net change of -18 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2023 was Deerfield Management, an estimated $29M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2023 was Macquarie Group, an estimated $9.19M sold.
Based on aggregated 13F filings for Q2 2023.